Hydrochloric Acid → HCID 86727233, Verbindung

(S)-5-(hydroxymethyl)oxazolidin-2-one (570 mg, 4.87 mmol, as described by Danielmeier, K.; Steckhan, E. Tet. Asymmetry, 6(5), 1995, 1181) and imidazole (331 mg, 4.87 mmol) were dissolved in dimethylformamide (5 mL) and cooled to 0° C. tert-Butylchlorodiphenylsilane (1.34 g, 4.87 mmol) was added dropwise at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 5 hours. The mixture was was poured into 0.5 N HCl (50 ml), and the resultant mixture was extracted with ethyl acetate. The layers were separated, and the organic phase was washed with saturated sodium bicarbonate, water and brine. The organic phase was dried over sodium sulfate and the solvent removed to afford crude material that was purified on a silica gel column (50% ethyl acetate in hexanes) to give the title compound (1.28 g, 74.0%). 1H NMR (300 MHz, DMSO-d6) δ: 1.0 (s, 9 H) 3.3-3.6 (m, 2 H) 3.6-3.9 (m, 2 H) 4.6-4.8 (m, 1 H) 7.3-7.8 (m, 11 H). MS (ES) (M+23)+: 278 for the Na+ adduct of C20H25NO3Si.

1. additionwas added dropwise at 0° C
2. extractionthe resultant mixture was extracted with ethyl acetate
3. customThe layers were separated
4. washthe organic phase was washed with saturated sodium bicarbonate, water and brine
5. dry with materialThe organic phase was dried over sodium sulfate
6. customthe solvent removed
7. customto afford crude material that
8. customwas purified on a silica gel column (50% ethyl acetate in hexanes)

ORD-Eintrag

ord-75a75725c2114ddf87894d87d4a7416e

Quelldatensatz

uspto-grants-2015_11

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US09187495B2